Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 259.19M P/E - EPS this Y -65.70% Ern Qtrly Grth -
Income -124.45M Forward P/E -1.50 EPS next Y -1.40% 50D Avg Chg -12.00%
Sales 169.36M PEG 0.07 EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.39 EPS next 5Y -16.40% 52W High Chg -51.00%
Recommedations 1.70 Quick Ratio 3.33 Shares Outstanding 81.96M 52W Low Chg 5.00%
Insider Own 0.96% ROA -13.91% Shares Float 64.53M Beta 1.18
Inst Own 78.11% ROE -81.10% Shares Shorted/Prior 2.99M/3.39M Price 4.29
Gross Margin -28.92% Profit Margin -73.48% Avg. Volume 473,401 Target Price 12.00
Oper. Margin -189.39% Earnings Date Nov 11 Volume 258,401 Change -3.60%
About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc. News
11/18/24 Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
11/15/24 Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/13/24 Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
11/13/24 Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
11/04/24 Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
11/04/24 Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children
11/01/24 Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
10/20/24 Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago
10/10/24 Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
09/20/24 Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/14/24 Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
09/11/24 Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
08/26/24 Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
08/23/24 Sutro Biopharma commences Phase II trial of luvelta for lung cancer
08/22/24 Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
08/15/24 Companies Like Sutro Biopharma (NASDAQ:STRO) Are In A Position To Invest In Growth
08/13/24 Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
08/13/24 Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
07/09/24 Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
05/31/24 Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
STRO Chatroom

User Image MrAnonymously Posted - 14 hours ago

$STRO gonna grab some on Monday

User Image FranzSturm Posted - 1 day ago

$STRO join at 2,58$ rebount

User Image venicia Posted - 2 days ago

$STRO What advancements will it from going lower?

User Image Cvfiore2001 Posted - 2 days ago

$STRO wonder if Steve cohen is still in here at an average of over 5 a share

User Image Dombak Posted - 2 days ago

$STRO I just added another 2,900. If the price is manipulated lower I will continue to add :)

User Image NotOfTheBody Posted - 3 days ago

$STRO Nonsensical at this price...I'll keep adding thank you. Way in oversold territory.

User Image Dombak Posted - 4 days ago

$STRO I think the revenue miss this Q combined with RFK fears provided an opportunity for the market manipulators to increase their short positions and effectively create a 'long-squeeze'. But with revenue forecast to rise next Q and a cash runway for another 5-6 Q's (even if EPS remains constant), the fundamentals are pretty good.

User Image Night_Owl_Biotech Posted - 4 days ago

$STRO is off 40% the last 7 trading days. This is the largest drop of 25 peer clinical-stage oncology focused bios with market caps between $150 & $650MM (see attachment). STRO's enterprise value (market cap - cash) = -$167MM. STRO is running a potential reg'l trial in certain ovarian cancers not suited for Elahere & has engaged a banker (Lazard) to find a long-term partner. Put simplest, it is worth investors efforts to fully research STRO as, though of course STRO could fail, its risk/reward profile is compelling again (especially if you believe stocks like STRO trade in cycles) Other clinical-stage oncology focused bios trading for well less than cash with near-term pot'l value inflection points/data reads incl $CMPX $ITOS & $ZNTL $BDTX trades slightly higher than cash but expects a Phase 2 data read in certain lung cancers in Q125 (BDTX's therapy was deemed "de-risked" by Piper Sandler after an interim read 2 months ago). This is not investment advice.

User Image Micio8387 Posted - 4 days ago

$STRO

User Image KY3000 Posted - 4 days ago

$STRO LFG you POS’S, knock it down to 2

User Image KY3000 Posted - 4 days ago

$STRO crazy block buys, 0 movement

User Image SylusAtreau Posted - 5 days ago

$STRO Lots of positive news coming out for Sutro Biopharma. Projected future earnings increased by analysts, initiated buy ratings and reiterated buy ratings by analysts, as well as increased rating by zacks.

User Image KY3000 Posted - 5 days ago

$STRO IMGN sold for 10$ billion, sutro is getting bought, I don’t know when

User Image KY3000 Posted - 5 days ago

$STRO I’m here till 2026, IMGN sold for 31$ a share, sutro bigger market, better safety profile

User Image SylusAtreau Posted - 5 days ago

$STRO There is no negative news. This is getting shorted before a future short squeeze. If you look at the charts this is cycular every month to every other month.

User Image Micio8387 Posted - 5 days ago

$STRO I sold this shit... 1.6k loss... never again garbage

User Image KY3000 Posted - 5 days ago

$STRO if retail keeps buying, 1.50$ for 2 years. Why I support administration full of sex offenders, going to blow this shit up by the same class of trash

User Image KY3000 Posted - 5 days ago

$STRO if retail buys, hedges won’t let it go up, they using AI, they know who’s buying/what their worth & when their bills due

User Image NotOfTheBody Posted - 5 days ago

$STRO .... .. ........ added at $2.70

User Image Micio8387 Posted - 6 days ago

$STRO crazy

User Image SylusAtreau Posted - 6 days ago

$STRO

User Image KY3000 Posted - 6 days ago

$STRO RFK not getting in, to many repubes in moderate states

User Image camraptor Posted - 1 week ago

$STRO just bought in again.

User Image Micio8387 Posted - 1 week ago

$STRO Something's wrong, -30 n 5 days is too much without any news

User Image BBQQ Posted - 1 week ago

$STRO POS

User Image Sillyspuh Posted - 1 week ago

$STRO oh my...

User Image Micio8387 Posted - 1 week ago

$STRO -30 in 5 days…

User Image KY3000 Posted - 1 week ago

$STRO Wall Street the nastiest ppl ever on earth, they are against all retail

User Image KY3000 Posted - 1 week ago

$STRO crazy

User Image SylusAtreau Posted - 1 week ago

$STRO

Analyst Ratings
JMP Securities Market Outperform Sep 16, 24
HC Wainwright & Co. Buy Sep 16, 24
Truist Securities Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 14, 24
Oppenheimer Outperform May 15, 24
Wedbush Outperform May 14, 24
HC Wainwright & Co. Buy May 14, 24
B of A Securities Buy May 8, 24
Piper Sandler Overweight Apr 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
NEWELL WILLIAM J CEO CEO Mar 14 Buy 7.7508 10,000 77,508 116,525 03/15/22
Petree Daniel H Director Director Feb 08 Option 5.33 14,277 76,096 22,265 02/09/22